Exclusive
I
BM is modifying its Watson software that recommends cancer treatments so that it reflects geographic differences in how patients are treated around the world, according to a recording of a staff meeting reviewed by STAT.
That represents a major shift for IBM on a venture that the company has aggressively promoted as having the potential to revolutionize medicine. It has long marketed Watson for Oncology as being based on the expertise of doctors at the prestigious New York cancer center who trained it. But some physicians at foreign hospitals that use or have considered buying the software have complained about irrelevant or inaccurate treatment recommendations and expressed dissatisfaction with its American bias.
Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!
SUBSCRIBE TODAYWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Authors
What BS. Hell I can do that.